Annual Report to Shareholders
Released
Released
Announcement PDF
ASX: RAC
Annual Report 2023
At the heart of cancer care
Corporate
Directory
DIRECTORS
Ms Mary Harney Non-Executive Chair
Dr Peter Smith Executive Director
Mr Phillip Lynch Non-Executive Director
COMPANY SECRETARY
Peter Webse
REGISTERED OFFICE
Level 36, Gateway, 1 Macquarie Place
Sydney NSW 2000
Ph: +61 2 8051 3043
Website: www.raceoncology.com
AUDITOR
Hall Chadwick WA
283 Rokeby Road
Subiaco WA 6008
SECURITIES EXCHANGE LISTING
Race Oncology Limited’s shares are listed on the
Australian Securities Exchange (ASX Code – RAC)
SHARE REGISTRY
Automic Registry Services
Level 5, 126 Phillip Street
Sydney NSW 2000
Ph: 1300 288 664
Race Oncology Limited
ACN 149 318 749
Contents
Chair Letter
2
2023 Key Highlights
4
Directors’ Report
6
Auditor’s Independence Declaration
24
Consolidated Statement of Profit or Loss
and Other Comprehensive Income
25
Consolidated Statement of Financial Position
26
Consolidated Statement of Changes in Equity
27
Consolidated Statement of Cash Flows
28
Notes to the Financial Statements
29
Directors’ Declaration
55
Independent Auditor’s Report
56
ASX Additional Information
61
Annual Report 2023
1
Chair
Letter
Dear fellow shareholders,
It is my privilege to welcome
you to Race Oncology’s
2023 Annual Report.
The past year has been a critical one for Race, with
important progress made in redefining the business
to maximise the commercial potential of bisantrene,
and ultimately positively impact the lives of people
living with cancer.
At the outset, it is worth reflecting on just some of the
major achievements and milestones reached by your
company through FY23. These have included:
– The release of a detailed commercial assessment
pointing to the major market potential of
bistantrene as an anti-cancer and cardioprotective agent;
– Strengthened relationships with global Key
Opinion Leaders (KOLs), specifically in the key
areas of oncology and cardio-protection;
– Preclinical progress made with the development
of our new bisantrene formulation, RC220,
which will enable delivery of the drug to patients
via a catheter in the forearm (peripheral IV)
and is critical to our clinical program moving
forward; and
– Continuing to grow Race’s international profile
and cementing key partnerships with major
medical institutions such as the City of Hope,
with whom we now have a global licence
agreement in place.
2
Race Oncology Limited
These accomplishments, along with other milestones
in FY2023, have laid the foundations for success
in getting bisantrene into the hands of patients
and partners.
In reflecting on the past year, it is also important to
acknowledge the changes to the Board and senior
management team to ensure the Company and
our lead asset, bisantrene, is suitably positioned
for commercial success.
I wish to extend my sincere thanks to my predecessor
as Chair, Dr John Cullity whose commitment to Race
was enduring. John retired from the Board postperiod, however we are fortunate to retain his support
as a major shareholder. My appointment as Chair
was part of a planned Board renewal strategy, which
also saw us welcome Dr Peter (Pete) Smith, initially
as Independent Non-Executive Director and now as
Executive Director (as reported post-period). Pete
brings exceptional experience in both healthcare and
capital markets – he is an outstanding appointment
for Race.
Pete stepped into the role following the resignation
of Damian Clarke-Bruce as CEO and Managing
Director. I would like to acknowledge Damian for the
many achievements he delivered through his time
with Race, including the collaboration with City of
Hope to support our discovery programs, contracting
Ardena to enable global GMP manufacturing,
and building important relations with clinicians,
international KOL’s and potential partners.
Broader renewal across Race’s management team
also saw the appointment of Dr Michelle Rashford
as Chief Medical Officer, who has significant
expertise in the successful development and
commercialisation of pharmaceuticals. Michelle is
experienced in oncology, virology, and immunology
indications.
Another notable change came with Dr Daniel
Tillett stepping away from the role of Executive
Director and Chief Scientific Officer in March 2023,
following four years of significant contribution to
the Company. Daniel remains a key player as our
major shareholder, and as announced on 22 August
2023, rejoined us as consultant to Race to support
of bisantrene’s clinical development. We warmly
welcome Daniel’s commitment and contribution
to Race. Finally, I would also like to recognise
the substantial contribution of Phil Lynch during
his time as CEO - we are fortunate to retain his
expertise on the Board as Non-Executive Director.
There is no question that the past year has been a
challenging one, and I recognise that this has been
reflected in the share price. At the time of writing,
we had just announced changes to the leadership
team designed to optimise the positioning of
bisantrene for success, with a particular focus
on short to medium term clinical and preclinical
deliverables. We have our heads down, working on
refocusing our bisantrene development strategy
and you have our commitment to swift action in this
regard. We look forward to updating the market on
our next strategic steps in due course.
FY23 included a detailed
commercial assessment
pointing to the major market
potential of bistantrene
as an anti-cancer and
cardio-protective agent.
We are confident in bisantrene - an asset which has a
long history of safety and efficacy in clinical trials. The
year ahead will see us move into the clinic again, with
an enhanced, IP-strengthened, formulation for the
benefit of patients. I wish to sincerely thank you for
your ongoing support of Race Oncology.
Mary Harney
Chair
Race Oncology
Annual Report 2023
3
2023 Key
Highlights
September 2022
September 2022
Race contracts the
Monash Fragment
Platform (MFP)
to complete a
fragment-based
screening program,
aimed at discovering
novel drugs that
inhibit the m6A RNA
demethylases FTO
and ALKBH5
Race develops a
new formulation
of bisantrene that
enables peripheral
(arm or leg vein)
intravenous (IV)
delivery to patients.
Race appoints
interim Chief
Medical Officer,
Dr Ajay Duggal of
Adnovate Clinical,
to replace Dr David
Fuller
December 2022
December 2022
Race submits a
Human Ethics
application to
commence a breast
cancer observational
study, led by
Associate Professor
Aaron Svedlov
Race appoints Mr
Damian ClarkeBruce as CEO and
Managing Director,
bringing 25 years
of international
BioPharma industry
experience
4
Race Oncology Limited
November 2022
November 2022
December 2022
Race announces it
has received written
feedback from the
FDA via a pre-IND
meeting, providing
important guidance
around Race’s
clinical plans
Race announces the
appointment of Mr
Danny Sharp as an
Independent NonExecutive Director
December 2022
February 2023
March 2023
Race announces
it has provided
support funding for
an MD Anderson
Cancer Center study
into extramedullary
Acute Myeloid
Leukaemia (EMD
AML), which will
seek to establish
the levels at which
extramedullary
disease is present in
AML and how these
patient needs may
differ
Human ethics
approval received
for the observational
stage of a planned
Phase 1/2b clinical
trial of Zantrene
in breast cancer
patients, to be
treated with
doxorubicin and
cyclophosphamide
and who have two or
more cardiovascular
risk factors
Race begins a
new collaborative
research project
with the University
of North Carolina at
Chapel Hill (USA)
to uncover at the
molecular level how
Zantrene protects
the heart from
chemotherapy
FY23 saw the development of a new formulation for
bisantrene to enable easier delivery to patients.
March 2023
March 2023
March 2023
April 2023
April 2023
Contract Research
Organisations
Resolutum Global,
Beyond Drug
Development, and
NSW Regional
Biospecimen &
Research Services,
are appointed
to support the
observational
stage of a Phase
1/2b clinical trial of
Zantrene in breast
cancer patients
Executive Director
and CSO Dr Daniel
Tillett announced
his resignation,
with Professor Tim
Hammond assuming
the role of Interim
CSO
Race received
$1.48 million via
the Research &
Development
(R&D) Tax Incentive
from the Australian
Taxation Office
(ATO) for FY22
Triangle Insights
releases a detailed
commercial
assessment of the
market potential
for bisantrene as a
cardio-protective
agent or dual cardioprotective and
anti-cancer agent in
breast, endometrial
and ovarian cancers
Ms Mary Harney
is appointed
Independent NonExecutive Chair
(NED) of Race, with
Dr John Cullity
remaining on the
Board as NonExecutive Director
May 2023
June 2023
June 2023
June 2023
Race appoints
internationally
experienced
biopharmaceutical
executive and
former physician, Dr
Michelle Rashford,
as Chief Medical
Officer (CMO),
taking over from
interim CMO, Dr
Ajay Duggal
Race transitions
back to the
international nonproprietary name of
bisantrene for use
when describing
the Company’s lead
asset in order to
increase presence
in the global clinical
community and
align with regulatory
expectations in most
major countries from
organisations like the
FDA, EMA & TGA
Race completes its
on-market share
buy-back program,
acquiring 634,881
shares for a total
consideration of
approximately
$1,276,598
(including brokerage
costs)
Dr Peter Smith as
appointed as NonExecutive Director,
replacing Daniel
Sharp
August 2023
(post period)
Race releases a
strategic update to drive
bisantrene’s commercial
partnering and
collaboration potential.
Changes announced to
the team, with Damian
Clarke-Bruce resigning as
CEO/Managing Director,
Dr Pete Smith appointed
Executive Director, Dr
Daniel Tillett engaged as
a consultant, and Dr John
Cullity retiring from the
Board.
At the time of writing,
the team was revisiting
the strategic update
to ensure delivery of
significant research
and clinical milestones
using current financial
resources.
Annual Report 2023
5
Directors’ Report
Directors' Report
30 June 2023
Your directors present their report, together with the financial statements of Race Oncology Limited (the Company, Race or
RAC), for the financial year ended 30 June 2023.
Information on directors
Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.
Mary Harney
Qualifications
Experience
Interest in shares and options
Directorships held in listed entities
Peter Smith
Qualifications
Experience
Non- Executive Chair (appointed as a Director 8 February 2021, appointed as Chair 20
April 2023)
BSc, BA (Fine Arts), MAICD FIML
Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing
leadership, governance and strategic advice across innovation industries such as
health, biotech and agriculture. She currently also serves as Chairman of private
Australian biotech Oncology One Pty Ltd, a cancer drug discovery company and
Microbio Limited, a diagnostic development company.
Ms Harney was formerly the CEO of Royal Australasian College of Surgeons; CEO of
Gardiner Research Foundation; COO and Director of Office of Cancer Research for
Peter MacCallum Hospital, and; COO of Cerylid Biosciences. Other former roles were
with CSL, Amrad, BIOPROPERTIES and Royal Melbourne Hospital.
Personal & related party relevant interests:
•
Mary Celicia Harney <MMA Super Fund A/C> - 23,400 Fully Paid Ordinary
Shares
Mary Celicia Harney – 110,392 Options exercisable at $3.32 expiring 3/03/2028
•
None
Executive Director (appointed as Non-Executive Director 28 June 2023, appointed as
Executive Director 21 August 2023)
PhD of the University of Cambridge in the field of cell-signalling
Interest in shares and options
Dr Peter Smith has over 30 years of experience in a broad range of activities in the
healthcare industry with a strong focus on therapeutics, especially oncology. He has been
involved in projects at all stages from concept to phase III clinical studies.
None
Directorships held in listed entities
None
Phillip Lynch
Non-Executive Director (appointed as a Director 1 June 2020, ceased to be CEO & MD
1 February 2023)
Graduate of Monash University with a Bachelor of Business in Marketing. Completed
postgraduate studies at University of Virginia’s Darden Business School (USA). Graduate
of the Australian Institute of Company Directors.
Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with
Johnson & Johnson. He is an experienced executive and board director, with a diverse
background across corporate development, strategy, financial performance, marketing
and governance.
In his former role as Vice President of Commercial Growth and Innovation at Johnson &
Johnson Asia Pacific (J&J AP), 2016 - 2019, Mr Lynch partnered with the Mergers and
Acquisitions team to drive the integration and growth of acquired businesses. He retired
from J&J AP in December 2019 following the >$2b acquisition and integration of a
significant Japanese business.
He is currently the Chair of Consumer Health Products Australia.
Qualifications
Experience
6
Race Oncology Limited
Directors' Report
30 June 2023
Information on directors (cont’d)
Phillip Lynch (cont’d)
Interest in shares and options
Personal & related party relevant interests:
•
2,000,000 Options exercisable at $2.65 expiring 29/11/2025
Lynch Eventide Holdings Pty Ltd <Lynch Family A/C> - 429,149
Fully Paid Ordinary Shares
None
•
Directorships held in listed entities
Damian Clarke-Bruce
Managing Director and Chief Executive Director (appointed 1 February 2023,
resigned 21 August 2023.)
Qualifications
Graduate of the Institute of Company Directors (GAICD) and holds a Master’s
in Science, with Postgraduate work in Business at Macquarie University and
Rehabilitation at University of Sydney. Completed Executive learning module
of exploring the Essential of Genetics in Harvard Medical School. Completed
Executive Education on Accounting and Finance in Harvard Business School.
Experience
Damian is an experienced international healthcare executive, having worked
in the biopharmaceutical and healthcare industries for over 25 years.
Prior to joining Race Oncology, Damian served as the Global/US Executive
Director of Marketing in Rare Disease for Pharming NV, a Netherlands/US
Biopharma Company. In this role, Damian was the Chair of the Global Launch
Leadership Team, overseeing drug commercialisation, including the
worldwide commercialisation of Leniolisb. In recognition of his work at
Pharming, Damian won the CEO award in 2022.
Damian’s career has also spanned multiple global pharmaceutical
companies, including Celgene, Novartis & Biogen. He has held leadership
roles within many executive teams across development/medical, market
access and commercialization. He has successfully taken products from the
clinic to blockbuster commercial status in highly specialised and complex
disease areas.
During his longest tenure at Novartis, Damian was the Australian Franchise
Head of both Neuroscience and Integrated Hospital Care, which led to a
succession role of Worldwide Executive Marketing Director in Neurology
(Switzerland) followed by the US Head of Marketing in Multiple Sclerosis.
Previous positions also included head of National Sales.
Underlying his leadership strength in biopharmaceuticals, Damian has also
been extensively involved in entrepreneurial healthcare. In 2006 he founded
the Bone & Joint Clinic, now BJC Health, in Sydney and served on multiple
industry boards, including Exercise & Sports Science Australia. He has
always been an active community coach & leader through sport and
contributes time with Surf Lifesaving Australia and community teams.
Interest in shares and options
Personal & related party relevant interests:
•
Damian Clarke-Bruce – 6,818 Fully Paid Ordinary Shares
•
Damian Clarke-Bruce – 755,671 Options exercisable at $3.30 lapsed on
21 August 2023.
Directorships held in listed entities
None
Annual Report 2023
7
Directors’ Report
Directors' Report
30 June 2023
John Cullity
Qualifications
Experience
Non-Executive Director (appointed as a Director 6 April 2018, ceased to be Chair on 20 April
2023 and retired as Non-Executive Director on 21 August 2023.)
MBBS, MRCP, MSc(Econs), MBA
Dr Cullity is Managing Director at BioSynergy Partners, a New York and Melbourne based
advisory recently spun out of Torreya – the renowned life sciences investment bank. He
additionally serves on the Boards of several life sciences companies including Ceramedix
(seeded by Torreya).
At Torreya, he provided strategic advisory on Mergers and Acquisitions, Partnering and
Financing to life-science companies worldwide. Prior to joining Torreya, he was a senior
member of the Business Development team at Sanofi Pharmaceuticals, where he led buy
side transactions in oncology and diabetes. Earlier in his career, Dr Cullity was Head of
Strategic Pricing and Reimbursement at Sanofi, Director of Health Economics at
Schering-Plough, and Consultant at A.T. Kearney. He has also worked at the World Bank
and the World Health Organisation.
Interest in shares and options
Directorships held in listed
entities
Daniel Sharp
Qualifications
Experience
Interest in shares and options
Directorships held in listed
entities
8
Race Oncology Limited
Dr Cullity graduated in Medicine and sub-specialised in haematology-oncology at QE II
Medical Centre, Perth. He holds a Bachelor of Medicine, Bachelor of Surgery from The
University of Western Australia; Membership of the Royal College of Physicians; Masters in
Health Economics from London School of Economics & Political Science, and MBA from The
Wharton School, University of Pennsylvania.
Personal & related party relevant interests:
•
Biosynergy Partners Pty Ltd - 6,102,194 Fully Paid Ordinary Shares
•
Craganorig Holdings, LLC - 2,000,000 Fully Paid Ordinary Shares
None
Non-Executive Director (appointed as a Director 5 December 2022, resigned 29
June 2023.)
Bachelor of Economics and Law, CFA
After commencing his career as a solicitor, Mr Sharp has had an extensive
investment banking career of more than 25 years where he has advised the boards
of technology and healthcare-based organisations on global capital markets. He has
an extensive network of institutional and private wealth investors.
None
Alcidion Group Limited (Non-Executive Director appointed 1 September 2021)
Botanix Pharmaceuticals Limited (Non-Executive Director appointed 22 March
2022)
ImpediMed Limited (Non-Executive Director appointed 1 July 2023)
Directors' Report
30 June 2023
Daniel Tillett
Qualifications
Executive Director and Chief Scientific Officer (appointed as a Director 17 September
2019, resigned 21 March 2023.)
Ph.D in Molecular Genetics & Biochemistry
Experience
Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private biotechnology company
in the genomics space. He was previously a Senior Lecturer within the School of
Pharmacy at La Trobe University where he lectured on biochemistry, biotechnology,
pharmacy, microbiology and virology. Dr Tillett’s Ph.D on the molecular genetics and
biochemistry of microcystin toxin production was awarded by the University of New
South Wales in 2000.
Interest in shares and options
Personal & related party relevant interests:
Directorships held in listed
entities
•
16,322,295 Fully Paid Ordinary Shares
•
2,000,000 Options exercisable at $2.65 expiring 29/11/2025
Simble Solutions Limited (Non-executive director appointed 16 February
2022 – resigned 3 July 2023)
Peter Webse
Qualifications
Experience
Company Secretary
B.Bus, FGIA, FCIS, FCPA.
Mr Webse has over 29 years' company secretarial experience and is the director of
Governance Corporate Pty Ltd, a company specialising in providing company
secretarial, corporate governance and corporate advisory services.
Principal activities
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at
the heart of cancer care.
Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical
history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and
compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, exploring anticancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA
pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesityassociated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of
cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is
actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene
for patients with cancer across the world.
Outlook
At the time of writing, Race Oncology (Race) had released an updated strategy (ASX: 8 August 2023) designed to maximise
the potential of bisantrene, leveraging its unique mechanisms of anti-cancer and cardio-protection.
Subsequent to the strategy’s release, the Company announced (ASX: 22 August 2023) that a core Board and Management
team would revisit the strategy, making appropriate adjustments to, and ultimately delivering on the primary focus of getting
bisantrene into the hands of partners and patients. At the time of writing, the team had commenced this review and is confident
that significant research and clinical milestones can be achieved using current financial resources.
Looking ahead, the Company expects to swiftly conclude the work on its strategy and announce next steps to the market.
Annual Report 2023
9
Directors’Report
Report
Directors'
30 June 2023
Overview of company performance
The table below sets out information about Race's earnings and movements in shareholder wealth for the past five years up
to and including the current financial year.
2023
$
NPAT ($'m)
Share price at year end ($))
Basic EPS (cents)
Total dividends (cents per share)
(9.92)
1.23
(6.17)
-
2022
$
(11.20)
1.95
(7.28)
-
2021
$
(6.34)
3.67
(4.84)
-
2020
$
(3.85)
0.70
(3.60)
-
2019
$
(3.66)
0.05
(4.60)
-
Meetings of directors
During the financial year, 11 meetings of directors (including committees of directors) were held. Attendances by each director
during the year were as follows:
Directors' Meetings
Number eligible to attend
Number attended
Mary Harney
11
10
Phillip Lynch
11
11
Peter Smith
-
-
Damian Clarke-Bruce
5
5
John Cullity
11
11
Daniel Tillett
8
8
Daniel Sharp
7
7
Operating results
The operating loss after providing for income tax amounted to $9,923,425 (2022: loss of $11,201,978); net cash used in
operating activities was $10,651,551 (2022: $6,257,837).
Dividends paid or recommended
No dividends were paid or are payable for the financial year (2022: Nil).
10
Race Oncology Limited
Directors' Report
30 June 2023
Review of operations
The following section summarises ASX updates from the 2023 financial year:
On 27 September 2022, Race announced that it had contracted the Monash Fragment Platform to complete a fragment-based
screening program, aimed at discovering novel drugs that inhibit the m6A ribonucleic acid (RNA) demethylases FTO and AlkB
Homolog 5 (ALKBH5). This program may lead to new IP (intellectual property), solely owned by Race for molecules targeting
cancer and other metabolic diseases.
On 28 September 2022 Race announced its researchers, led by Dr Benjamin Buckley, in collaboration with the University of
Wollongong, had developed a new formulation of bisantrene that enables peripheral (arm or leg vein) intravenous delivery to
patients. This formula provides clinicians with an easier to use alternative to the current central line formulation, adds new IP
and is well suited to solid tumour application.
Race scientists Professor Michael Kelso and Dr Daniel Tillett, in collaboration with researchers from the University of
Newcastle were awarded $999,998 on 20 September 2022 by the Medical Research Future Fund for a grant entitled
“Cardiovascular disease and cancer: identifying shared disease pathways and pharmacological management.”
On 18 October 2022, Race presented at the Australian Microcap Conference in Melbourne. Building on this presentation,
Race management met with current investors in Melbourne through a shareholder information session, as well as professional
investors via roadshow.
On 11 November 2022, Race announced the appointment of an interim Chief Medical Officer, Dr Ajay Duggal of Adnovate
Clinical, replacing Dr David Fuller, effective 11 November 2022.
On 23 November 2022, Race announced it had received written feedback from the United States (US) Food and Drug
Administration (FDA) via a pre-investigational new drug (IND) meeting. This formal correspondence provided important
guidance around Race’s clinical plans. The clinical hold issues from the 2019 IND application were satisfactorily addressed,
providing Race a viable path for the clinical development of bisantrene in the US and commercial optionality.
On 5 December 2022, Race announced the appointment of Mr Danny Sharp as an Independent Non-Executive Director.
Danny brings extensive capital markets experience and adds further independence to the Race Board.
On 9 December 2022, Race announced submission of a Human Ethics application to commence a breast cancer observational
study. The study will be led by Professor Aaron Sverdlov, a highly credentialed cardiologist who co-chairs the National CardioOncology working group. The study will identify the rate and level of heart damage caused by standard of care anthracycline
chemotherapy.
On 14 December 2022, Race announced the appointment of Mr Damian Clarke-Bruce as Chief Executive Officer and
Managing Director, effective from 1 February 2023. Damian holds over 25 years of international BioPharma industry
experience, having worked previously at Pharming, Novartis US & Global, Celgene, Zimmer, Biogen, BJC Health, Pharmacia
& Searle Pharmaceuticals.
On 22 December 2022, Race announced it had provided support funding for an MD Anderson Cancer Center study into
extramedullary AML. The study, led by Dr Maro Ohanian, will seek to establish the levels at which extramedullary disease is
present in AML and how the needs of this patient cohort may differ.
On 23 December 2022, Race provided an update on its clinical and preclinical programs and a summary of expected news
for 2023.
On 1 February 2023, Race announced it had received human ethics approval from the Hunter New England Human Research
Ethics Committee (NSW, Australia) for the observational stage of a planned Phase 1/2b clinical trial of bisantrene in breast
cancer patients, to be treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors.
On 2 March 2023, Race announced it had begun a collaborative research project with the University of North Carolina at
Chapel Hill (USA) to uncover at the molecular level how bisantrene protects the heart from chemotherapy. The program is
being led by leading international cardio-oncologist Dr Brian Jensen of the McAllister Heart Institute.
On 13 March 2023, Race announced it had appointed the Contract Research Organisations Resolutum Global, Beyond Drug
Development, and NSW Regional Biospecimen & Research Services, to support the observational stage of a Phase 1/2b
clinical trial of bisantrene in breast cancer patients treated with doxorubicin and cyclophosphamide and who have two or more
cardiovascular risk factors.
Annual Report 2023
11
Directors’ Report
Directors' Report
30 June 2023
Review of operations (cont’d)
On 24 March 2023, Race announced that Executive Director and CSO Dr Daniel Tillett had advised his decision to step down
from his roles. Dr Tillett went on to provide ongoing support through June 2023 to ensure a smooth transition of his CSO
responsibilities to the Race team, with oversight from Professor Tim Hammond, who would assume the role of Interim CSO.
On 27 March 2023, Race announced that it had received $1.48 million via the Research & Development Tax Incentive from
the Australian Taxation Office for the financial year ended 30 June 2022.
On 4 April 2023, Race provided investors with a summary of market research conducted by Triangle insights, commissioned
to better understand the commercial potential for lead asset, bisantrene as a cardio-protective and anticancer agent in settings
where anthracyclines are typically used.
On 14 April 2023, Race released a detailed commercial assessment of the market potential for bisantrene as a cardioprotective agent or dual cardio-protective and anti-cancer agent in breast, endometrial and ovarian cancers.
On 20 April 2023, Race announced that Ms Mary Harney had been appointed Independent Non-Executive Chair, while Dr
John Cullity was to remain on the Board as Non-Executive Director. Ms Mary Harney has been a Non-Executive Director of
Race Oncology since 8 February 2021 and as an accomplished Non-Executive Director and life science executive, brings
deep understanding of academic and applied life science research, in addition to biopharmaceutical regulatory affairs and
commercialisation capability.
On 9 May 2023, Race announced the appointment of Dr Michelle Rashford as Chief Medical Officer (CMO), taking over from
interim CMO, Dr Ajay Duggal. Dr Rashford is an internationally experienced biopharmaceutical executive and former physician,
with expertise in the successful development and commercialisation of pharmaceuticals
Share your feedback
Discover